Prat et al. reported that the HER2DX combined prognostic score, consisting of tumor size, nodal status, TILs, intrinsic molecular subtype, and 13 individual genes, was significantly associated with disease-free survival in early stage HER2-positive breast cancer [26]. This evidence concerns the gene ERBB2 and breast carcinoma.